药明生物(02269)今日盘中大涨5%,主要受益于多方利好因素的推动。
一方面,随着新冠疫情影响逐步减弱,全球医药创新研发需求正在温和复苏。据行业分析指出,2025年是医疗健康产业复苏的大好时机,未来CXO、创新药等赛道有望迎来新的发展机遇。作为国内领先的医药CRO企业,药明生物在未来可期望获得更多的研发订单。
另一方面,北水资金持续流入也为药明生物的股价上涨注入了动力。数据显示,北水资金周三携巨资加注四大科技龙头股,其中就包括药明生物。在资金持续流入的情况下,股价表现向好可以期待。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.